Results 11 to 20 of about 12,405 (251)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

AIDS Research and Therapy, 2020
Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors.
Aurelio Orta-Resendiz, Roberto A. Rodriguez-Diaz, Luis A. Angulo-Medina, Mario Hernandez-Flores, Luis E. Soto-Ramirez   +4 more
doaj   +2 more sources

Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling aims to understand how a drug is absorbed, distributed, metabolized, excreted, and acts in a human or animal body. The Simcyp Simulator is a well‐known commercial PBPK/PD simulation software offering many options.
Onasanwo AM, Mittapelly N, Shireman L, Vinden B, McNally K, Craig J, Bois FY.   +6 more
europepmc   +2 more sources

Using an automated decision support tool to improve HIV prescribing: A feasibility study. [PDF]

HIV Med
Abstract Objectives The selection of antiretroviral therapy (ART) regimens for people living with HIV is complex and dependent on individual and clinician‐perceived risk factors and preferences. The British HIV Association (BHIVA) advocates cost‐effective prescribing and shared decision‐making between patients and clinicians.
Ireland AT, Ward J, Dolby H, Lawrence C.
europepmc   +2 more sources

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review

Journal of the International AIDS Society, 2022
Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children.
C. Townsend, J. O’Rourke, Edith B. Milanzi, I. Collins, A. Judd, H. Castro, M. Vicari, J. Jesson, V. Leroy, F. Renaud, M. Penazzato   +10 more
semanticscholar   +1 more source

The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo

Cancers, 2021
Simple Summary Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. Serrated adenocarcinoma (SAC) has been recently recognized by the WHO as a histological CRC with bad prognosis.
Begoña Alburquerque-González, Á. Bernabé-García, Manuel Bernabé-García, J. Ruiz-Sanz, Fernando F. López-Calderón, L. Gonnelli, L. Banci, J. Peña-García, I. Luque, F. J. Nicolás, María Luisa Cayuela-Fuentes, E. Luchinat, H. Pérez‐Sánchez, S. Montoro-García, P. Conesa‐Zamora   +14 more
semanticscholar   +1 more source

Raltegravir monohydrate [PDF]

Acta Crystallographica Section E Structure Reports Online, 2013
The hydrated title compound [systematic name:N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-{1-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-ylcarbonyl)amino]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide monohydrate], C20H21FN6O5·H2O, is recognised as the first HIV integrase inhibitor.
Yamuna, T. S., Jasinski, Jerry P., Anderson, Brian J., Yathirajan, H. S., Kaur, Manpreet   +4 more
openaire   +4 more sources

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. [PDF]

PLoS ONE, 2009
Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in ...
Aylin Yilmaz, Magnus Gisslén, Serena Spudich, Evelyn Lee, Anura Jayewardene, Francesca Aweeka, Richard W Price   +6 more
doaj   +1 more source

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

Journal of Antimicrobial Chemotherapy, 2021
OBJECTIVES The second-generation integrase strand transfer inhibitor (INSTI) bictegravir is becoming accessible in low- and middle-income countries (LMICs), and another INSTI, cabotegravir, has recently been approved as a long-acting injectable.
E. Ndashimye, Yue Li, Paul S Reyes, Mariano Avino, Abayomi S. Olabode, C. Kityo, Fred Kyeyune, I. Nankya, M. Quiñones-Mateu, Stephen D. Barr, E. Arts   +10 more
semanticscholar   +1 more source

Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. [PDF]

PLoS ONE, 2014
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV infection, has been implicated in HAART-associated cardiovascular complications.
Xiaoxuan Zhang, Risheng Cao, Runping Liu, Renping Zhao, Yi Huang, Emily C Gurley, Phillip B Hylemon, William M Pandak, Guangji Wang, Luyong Zhang, Xiaokun Li, Huiping Zhou   +11 more
doaj   +1 more source

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

Journal of Antimicrobial Chemotherapy, 2021
Background To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1.
C. Herrera, J. Lwanga, M. Lee, S. Mantori, Alieu Amara, L. Else, S. D. Penchala, D. Egan, E. Challenger, L. Dickinson, M. Boffito, R. Shattock, S. Khoo, J. Fox   +13 more
semanticscholar   +1 more source